Biologics have changed expectation and outcomes for rheumatoid arthritis (RA). However,
the optimal duration and sequence of therapy for this disease has yet to be determined. Also, …

Objective To determine whether quality of life in patients with systemic lupus erythematosus
(SLE) measured by the Short Form 36 (SF‐36) changes over time and which patient‐ and …

Objective Epidemiologic assessments of sufficiently large populations are required in order
to obtain robust estimates of disease prevalence and incidence, particularly when exploring …

Background Elevated tumor necrosis factor (TNF)-α likely contributes to the excess
cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in …

Background Individuals with rheumatoid arthritis (RA) are at risk of developing cardiovascular
disease (CVD), but patient perceptions of CVD are not routinely assessed. We performed …

Objective To evaluate excess mortality over time, comparing rheumatoid arthritis (RA)
patients with the general population. Methods We computed all‐cause mortality rates among …

Objective. We review available safety data for use of currently approved tumor necrosis factor
(TNF) inhibitors during pregnancy and lactation and suggest guidelines for use of these …

Objective To investigate coronavirus disease 2019 (COVID-19) hospitalization risk in
patients with immune-mediated inflammatory diseases (IMIDs) compared with matched non-IMID …

Objective: To validate a model which predicts progression from undifferentiated arthritis (UA)
to RA, in a Canadian UA cohort. Methods: The prediction rule, comprising variables which …

Background While heart failure (HF) is associated with elevations in tumor necrosis factor (TNF)α,
several trials of TNF antagonists showed no benefit and possibly worsening of disease …